Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Individuals eligible to participate in this study must meet all of the following inclusion criteria:~* ≥18 years of age~* Confirmed diagnosis of LEMS~* Normal respiratory function~* Normal swallowing function~* If receiving peripherally acting cholinesterase inhibitors a stable dose is required for at least 7 days prior to Screening.~* If receiving oral immunosuppressants a stable dose is required for at least 90 days prior to Screening.~* Negative pregnancy test for females of childbearing potential~* If sexually active, willing to use 2 acceptable methods of contraception~* Willing to perform all study procedures as physically possible.~* Willing and able to provide written informed consent after the nature of the study has been explained and prior to the start of any research-related procedures.~Exclusion Criteria: Individuals who meet any of the following exclusion criteria are not eligible to participate in the study:~* History of epilepsy or seizure.~* Known active brain metastasis.~* Use of Fampridine (4-aminopyridine), and any form of 3,4-diaminopyridine other than the IP provided, such as amifampridine base or Firdapse, during the study.~* Use of medications known to lower the epileptic threshold within 7 days or 5 half-lives.~* Use of medications which inhibit neuromuscular junction function within 7 days or 5 half-lives.~* Use of IVIG, plasmapheresis (plasma exchange), or immunoadsorption within 90 days~* Use of guanidine hydrochloride within 7 days~* Use of rituximab within 12 months~* History of drug allergy to any pyridine-containing substances or any amifampridine phosphate excipient(s).~* Use of any other investigational productwithin 30 days~* Treatment with a concomitant medication that prolongs the QT/QTc interval within 7 days or 5 half-lives.~* Treatment with sultopride (4-amino-N-\[(1-ethylpyrrolidin-2-yl)methyl\]-5-ethylsulfonyl-2-methoxybenzamide) within 7 days.~* An abnormal electrocardiogram (ECG).~* Documented history of arrhythmias.~* History of additional risk factors for torsade de pointes.~* Breastfeeding or pregnant or planning to become pregnant (self or partner) at any time during the study.~* Likely or expected to require treatment for cancer within 3 months (90 days) after entering.~* History of severe renal impairment or evidence of severe renal impairment~* Any condition that places the patient at high risk of poor treatment compliance or of not completing the study.~* History of uncontrolled asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
- Amifampridine Phosphate (Type: EXPERIMENTAL): Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).